KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Treasury Shares (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 12 years of Treasury Shares data on record, last reported at $18.6 billion in Q4 2025.

  • For Q4 2025, Treasury Shares rose 22.72% year-over-year to $18.6 billion; the TTM value through Dec 2025 reached $18.6 billion, up 22.72%, while the annual FY2025 figure was $18.6 billion, 22.72% up from the prior year.
  • Treasury Shares reached $33.7 million in Q4 2025 per REGN's latest filing, up from $32.7 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $33.7 million in Q4 2025 and bottomed at -$17.7 million in Q2 2021.
  • Average Treasury Shares over 5 years is $12.5 million, with a median of $19.9 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: soared 545.87% in 2021, then grew 14.36% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $7.4 billion in 2021, then surged by 39.72% to $10.4 billion in 2022, then rose by 21.32% to $12.6 billion in 2023, then rose by 20.76% to $15.2 billion in 2024, then increased by 22.72% to $18.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $18.6 billion in Q4 2025, $17.9 billion in Q3 2025, and $17.3 billion in Q2 2025.